As an approach, we took advantage that a selective MEK1/2 inhibitor trametinib, which blocks ERK activation, was recently approved for the treatment of unresectable or metastatic melanoma with BRAFV600E or BRAFV600K mutations by the US Food and Drug Administration as a monotherapy and in combination with dabrafenib [22]. This evidence concerns the gene MAP2K1 and metastatic melanoma.